These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 38730553

  • 1. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L, Chen L, Liu X, Huang Z, Zheng Y, Tang K, Jiang X, Chen P.
    Rheumatology (Oxford); 2024 Sep 01; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.
    Alexander S, Fleming DH, Mathew BS, Varughese S, Jeyaseelan V, Tamilarasi V, Jacob CK, John GT.
    Ther Drug Monit; 2014 Aug 01; 36(4):423-32. PubMed ID: 25014074
    [Abstract] [Full Text] [Related]

  • 3. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM, Reinders ME, den Hartigh J, Huizinga TW, Rabelink AJ, de Fijter JW, Berger SP.
    Lupus; 2013 Feb 01; 22(2):171-9. PubMed ID: 23257398
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A, Woillard JB, Decramer S, Fila M, Guigonis V, Tellier S, Morin D, Sordet M, Saint-Marcoux F, Harambat J.
    Pediatr Nephrol; 2021 Feb 01; 36(2):341-347. PubMed ID: 32856157
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
    Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI.
    Semin Arthritis Rheum; 2011 Feb 01; 40(4):307-13. PubMed ID: 20655577
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
    Kittanamongkolchai W, Rukrung C, Supasiri T, Lertjirachai I, Somparn P, Chariyavilaskul P, Avihingsanon Y.
    Lupus; 2013 Jun 01; 22(7):727-32. PubMed ID: 23651860
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.
    Łuszczyńska P, Pawiński T.
    Ther Drug Monit; 2015 Dec 01; 37(6):711-7. PubMed ID: 26034895
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
    Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, Funck-Brentano C, Piette JC, Amoura Z.
    Arthritis Rheum; 2010 Jul 01; 62(7):2047-54. PubMed ID: 20506558
    [Abstract] [Full Text] [Related]

  • 9. Long-term renal survival of paediatric patients with lupus nephritis.
    Demir S, Gülhan B, Özen S, Çeleğen K, Batu ED, Taş N, Orhan D, Bilginer Y, Düzova A, Ozaltin F, Topaloğlu R.
    Nephrol Dial Transplant; 2022 May 25; 37(6):1069-1077. PubMed ID: 33826705
    [Abstract] [Full Text] [Related]

  • 10. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.
    Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF.
    Arthritis Res Ther; 2010 May 25; 12(6):R217. PubMed ID: 21176194
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF.
    Cochrane Database Syst Rev; 2018 Jun 29; 6(6):CD002922. PubMed ID: 29957821
    [Abstract] [Full Text] [Related]

  • 12. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM.
    Lupus; 2019 Apr 29; 28(5):613-620. PubMed ID: 30871425
    [Abstract] [Full Text] [Related]

  • 13. Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.
    Abd Rahman AN, Tett SE, Abdul Gafor HA, McWhinney BC, Staatz CE.
    Br J Clin Pharmacol; 2015 Nov 29; 80(5):1064-75. PubMed ID: 25959850
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL.
    Ann Rheum Dis; 2016 Jan 29; 75(1):30-6. PubMed ID: 25550339
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N, Kurian J, Agarwal V, Bhadauria D, Behera M, Yacha M, Kushwaha R, Agrawal V, Jain M, Gupta A.
    Lupus; 2020 Jul 29; 29(8):845-853. PubMed ID: 32437258
    [Abstract] [Full Text] [Related]

  • 16. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 29; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P, Pawiński T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M.
    Eur J Clin Pharmacol; 2019 Mar 29; 75(3):371-379. PubMed ID: 30430214
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.
    Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL.
    Ann Rheum Dis; 2020 Aug 29; 79(8):1070-1076. PubMed ID: 32448782
    [Abstract] [Full Text] [Related]

  • 19. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V.
    Lupus; 2018 Apr 29; 27(4):647-656. PubMed ID: 29105558
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P.
    Clin Pharmacokinet; 2008 Apr 29; 47(4):277-84. PubMed ID: 18336056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.